Sabba Stephen L 4
4 · LIGAND PHARMACEUTICALS INC · Filed Mar 5, 2026
Insider Transaction Report
Form 4
Sabba Stephen L
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-03$69.51/sh+2,034$141,383→ 35,827 total - Sale
Common Stock
[F1]2026-03-03$201.50/sh−2,034$409,851→ 33,793 total - Exercise/Conversion
Non- Qualified Stock Option (right to buy)
[F2]2026-03-03−2,034→ 0 totalExercise: $69.51Exp: 2026-05-23→ Common Stock (2,034 underlying)
Footnotes (2)
- [F1]These securities, as represented in Column 5, includes the grant of 1,209 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 6, 2025, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 10 June 2025, which was filed to reflect the 2025 Meeting grant.
- [F2]These securities, as represented in Column 5, were acquired by a grant of 2,329 shares approved by the Board of Directors of the Company at the 2016 Meeting, as previously reported on the Reporting Person's Form 4, dated 25 May 2016. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,034 shares and the exercise price adjusted to $69.51 pursuant to the OmniAb Inc. separation from the Company.
Signature
/s/ Stephen L. Sabba|2026-03-05